Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,09 USD | +0,59% | -0,39% | -45,33% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 418 mln. 388 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -42,69 mln. | Nettowinst (verlies) 2025 * | -72 mln. -66,82 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-8,93
x | K/w-verhouding 2025 * |
-5,85
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,86% |
Recentste transcriptie over Anavex Life Sciences Corp.
1 dag | +0,59% | ||
1 week | -0,39% | ||
Lopende maand | -0,97% | ||
1 maand | -3,96% | ||
3 maanden | -46,98% | ||
6 maanden | -24,26% | ||
Lopend jaar | -45,33% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 01-10-15 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Tom Skarpelos
FOU | Founder | 57 | 23-01-04 |
Jiong Ma
CHM | Chairman | 60 | 25-05-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.08% | 0 M€ | 0,00% | - | |
0.07% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 5,09 | +0,59% | 978 032 |
27-03-24 | 5,06 | +4,55% | 932 846 |
26-03-24 | 4,84 | +6,37% | 1 343 834 |
25-03-24 | 4,55 | -2,36% | 1 354 802 |
22-03-24 | 4,66 | -8,81% | 1 299 203 |
uitgestelde koers Nasdaq, 28 maart 2024 om 21:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-45,33% | 418 mln. | |
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |